obesity drug news today glp-1 october 23 2025 Pharma Giants Bet on Next-Generation Treatments to Sustain Growth GLP-1 and Dual GIP/GLP-1 Agonists
Description
For example, clinical trials for semaglutide at a 2.4 mg dose showed that 44.2% of participants experienced nausea, compared to 17.4% in the placebo group
Individuals have a higher risk of gaining the weight back if they do not keep up with the healthy lifestyle changes they made
21 PetriMKimMYKalunianKCGrossmanJHahnBHSammaritanoLRet al
Diabetes Care 44(2):479488
OCR was determined with the Seahorse technology
[DOI] [PMC free article] [PubMed] [Google Scholar] 95.Kelly AS, Auerbach P, Barrientos-Perez M, Gies I, Hale PM, Marcus C, et al
